



VACCINE ADMINISTRATION PARTNERS PROGRAM (VAPP) – ENTERPRISE

MARCH 2023

ABOUT VAPP

As part of the Australian Government’s continued COVID-19 response, the Vaccine Administration Partners Program (VAPP) Panel has been established to support vaccination of Australians in range of employment and community settings.

The VAPP enables access to COVID-19 Immunisation Providers (IProviders) by businesses, peak groups, not-for-profit organisations, state and territories, local governments, and Commonwealth agencies.

IProviders can be used by organisations wanting to provide COVID-19 vaccines to employees, subcontractors and employees of partner organisations. This can be done either as a standalone vaccine administration, or as part of co-administration with the seasonal influenza vaccine.

USING THE PANEL

To utilise the [Panel](#), organisations source a suitable IProvider and then enter into a binding commercial arrangement with the IProvider. All costs associated with the vaccination program are the responsibility of the engaging organisation. The Commonwealth does not provide any financial assistance – only the supply of COVID-19 vaccines.

The IProvider will then seek Commonwealth Government approval of the binding commercial arrangement, following which the IProvider will be able to order the vaccines and commence vaccinations. This process can take up to three weeks, so please keep this timeframe in mind.

In line with the latest [ATAGI advice released in February 2023](#), VAPP is also helping to facilitate co-administration of COVID-19 booster doses alongside influenza vaccines for eligible groups. [Co-administration of COVID-19 vaccines](#) is safe and has numerous benefits, including increasing vaccination uptake and helping to reduce staff absenteeism over the winter months.



Contacts

**Please right click over image to follow hyperlink.*

